Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-30T14:26:55.033Z Has data issue: false hasContentIssue false

P.029 Endovascular therapy for cerebral venous thrombosis: an international survey

Published online by Cambridge University Press:  24 May 2024

BA Brakel
Affiliation:
(Vancouver)
AD Rebchuk
Affiliation:
(Vancouver)*
J Ospel
Affiliation:
(Calgary)
MK Heran
Affiliation:
(Vancouver)
M Goyal
Affiliation:
(Calgary)
MD Hill
Affiliation:
(Calgary)
Z Miao
Affiliation:
(Beijing)
Y Chen
Affiliation:
(Taipei)
S Sacco
Affiliation:
(L’Aquila)
S Yaghi
Affiliation:
(Providence)
M Ton
Affiliation:
(Hanoi)
G Thomalla
Affiliation:
(Hamburg)
G Boulouis
Affiliation:
(Tours)
H Yamagami
Affiliation:
(Osaka)
BC Campbell
Affiliation:
(Parkville)
J Raymond
Affiliation:
(Montreal)
G Saposnik
Affiliation:
(Toronto)
TN Nguyen
Affiliation:
(Boston)
TS Field
Affiliation:
(Vancouver)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Cerebral venous thrombosis (CVT) is a rare cause of stroke, with 10–15% of patients experiencing dependence or death. The role of endovascular therapy (EVT) in the management of CVT remains controversial and practice patterns are not well-known. Methods: We distributed a comprehensive 53-question survey to neurologists, neuro-interventionalists, neurosurgeons and other relevant clinicians globally from May 2023 to October 2023. The survey asked about practice patterns and perspectives on EVT for CVT and assessed opinions regarding future clinical trials. Results: The overall response rate was 31% (863 respondents from 2744 invited participants) across 61 countries. A majority (74%) supported use of EVT for certain CVT cases. Key considerations for EVT included worsening level of consciousness (86%) and other clinical deficits (76%). Mechanical thrombectomy with aspiration (22%) and stent retriever (19%) were the most utilized techniques, with regional variations. Post-procedurally, low molecular weight heparin was the predominant anticoagulant administered (40%), although North American respondents favored unfractionated heparin. Most respondents supported future trials of EVT (90%). Conclusions: Our survey reveals significant heterogeneity in approaches to EVT for CVT, highlighting the necessity for adequately powered clinical trials to guide standard-of-care practices.

Type
Abstracts
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation